Abstract
Advances in diagnosis and treatment have dramatically impacted morbidity and mortality from cardiovascular disease over the past several decades. 1 The discovery in 1960 of stem cells capable of regeneration and repair sparked interest in a new mode of therapy for heart disease beyond pharmaceuticals and cardiac devices.2 Over the past 10 years, work has focused on five key cell types - the endothelial mononuclear progenitor cell, the autologous skeletal myoblast, the allogeneic mesenchymal stem cell, the resident cardiac stem cell, and the human embryonic stem cell - as potential therapeutic agents, which may further contribute to gains in treating cardiovascular disease. This chapter aims to review these cell types, their preclinical underpinnings, the nascent clinical studies, and limitations observed in their use.
| Original language | English (US) |
|---|---|
| Title of host publication | Advances in Vascular Medicine |
| Publisher | Springer |
| Pages | 131-151 |
| Number of pages | 21 |
| ISBN (Print) | 9781848826366 |
| DOIs | |
| State | Published - Dec 1 2010 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Cell therapy for cardiovascular disease. / Murrow, Jonathan R; Dhawan, Saurabh S.; Quyyumi, Arshed A.
Advances in Vascular Medicine. Springer, 2010. p. 131-151.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Cell therapy for cardiovascular disease
AU - Murrow, Jonathan R
AU - Dhawan, Saurabh S.
AU - Quyyumi, Arshed A.
PY - 2010/12/1
Y1 - 2010/12/1
N2 - Advances in diagnosis and treatment have dramatically impacted morbidity and mortality from cardiovascular disease over the past several decades. 1 The discovery in 1960 of stem cells capable of regeneration and repair sparked interest in a new mode of therapy for heart disease beyond pharmaceuticals and cardiac devices.2 Over the past 10 years, work has focused on five key cell types - the endothelial mononuclear progenitor cell, the autologous skeletal myoblast, the allogeneic mesenchymal stem cell, the resident cardiac stem cell, and the human embryonic stem cell - as potential therapeutic agents, which may further contribute to gains in treating cardiovascular disease. This chapter aims to review these cell types, their preclinical underpinnings, the nascent clinical studies, and limitations observed in their use.
AB - Advances in diagnosis and treatment have dramatically impacted morbidity and mortality from cardiovascular disease over the past several decades. 1 The discovery in 1960 of stem cells capable of regeneration and repair sparked interest in a new mode of therapy for heart disease beyond pharmaceuticals and cardiac devices.2 Over the past 10 years, work has focused on five key cell types - the endothelial mononuclear progenitor cell, the autologous skeletal myoblast, the allogeneic mesenchymal stem cell, the resident cardiac stem cell, and the human embryonic stem cell - as potential therapeutic agents, which may further contribute to gains in treating cardiovascular disease. This chapter aims to review these cell types, their preclinical underpinnings, the nascent clinical studies, and limitations observed in their use.
UR - http://www.scopus.com/inward/record.url?scp=84892106608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892106608&partnerID=8YFLogxK
U2 - 10.1007/978-1-84882-637-3_8
DO - 10.1007/978-1-84882-637-3_8
M3 - Chapter
SN - 9781848826366
SP - 131
EP - 151
BT - Advances in Vascular Medicine
PB - Springer
ER -